[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,252,0,25,[9,45,74,106,126,161,187,218,253,289,318,361,386,408,429,459,484,506,527,548,569,589,611,641,662],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100617321","omnipod-5-a-french-prospective-multicentric-study-in-real-world-optimal-b-100617321",false,"NCT07317102","Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)","Inclusion Criteria:\n\n* Patient with T1D aged ≥ 2 years.\n* Patient prescribed, less than a year ago, a commercially available confi guration of the Omnipod 5 System using a FreeStyle Libre 2 Plus sensor.\n* Patient has never used the Omnipod 5 System prior to inclusion.\n* Patient has not objected to the use of their personal data for this study.\n* Patient or legal guardian has an email address and mobile phone number.\n* Patient (and legal guardians if the patient is a minor) is able to understand study information and Non-Opposition form.\n* Patient (and legal guardians if the patient is a minor) is able to understand and complete questionnaires in French.\n* Patient is covered by the local social security system\n\nExclusion Criteria:\n\n* Patient is currently pregnant.\n* Patient presents an allergy to the materials of the Omnipod 5 System (patch, cannula, CGM).\n* Patient is unable to be followed by the same investigation site for the duration of the study or is unwilling or unable to maintain contact with the healthcare professional.\n* Patient is already participating in a clinical trial or in another study precluding their participation in other studies.\n* Adult under guardianship, curatorship or tutorship.\n* Adult otherwise deprived of liberty.","ALL","2 Years",{"count":19,"type":20},152,"ESTIMATED","12 Months","OBSERVATIONAL","The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.",[25,26,27],"Diabetes","Type 1 Diabetes","Diabetes Mellitus",[29,30,31],"Omnipod","Automated Insulin Delivery","Post-market Registry","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2026-03-16",{"date":40,"type":20},"2027-11",{"name":42,"class":43},"Insulet Corporation","INDUSTRY",24,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100601857","streamlined-denervation-with-spyral-for-an-optimized-treatment-spyral-swyft-in-subjects-with-uncontrolled-hypertension-100601857","NCT07115953","Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension","Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)","SWYFT","Inclusion Criteria:\n\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)\n4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery anatomy\n2. Individual has undergone prior renal denervation\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73m2\n6. Individual has one or more episode(s) of orthostatic hypotension\n7. Individual is pregnant, nursing or planning to become pregnant\n8. Individual has documented primary pulmonary hypertension\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%","18 Years",{"count":55,"type":20},130,"INTERVENTIONAL",[58],"NA","The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.",[61,62,63,64,27],"Hypertension","Vascular Diseases","Cardiovascular Diseases","Chronic Kidney Diseases","2026-06-29",{"date":33,"type":36},{"date":68,"type":36},"2025-09-22",{"date":70,"type":20},"2029-12-31",{"name":72,"class":43},"Medtronic Vascular",21,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100322739","early-tracking-of-childhood-health-determinants-etched-study-100322739","NCT03481829","Early Tracking of Childhood Health Determinants (ETCHED) Study","Early Tracking of Childhood Health Determinants Study","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Pregnant women aged 18 years or older (pregnancy confirmed by urine or serum pregnancy test, or ultrasound examination)\n2. American Indian or Hispanic by self-report\n3. Agree to continue with research study participation (both mother and their offspring), for at least 3 years after delivery.\n\nIn case where a pregnant mother is carrying multiple fetuses (multiple pregnancy), she will be eligible to participate in this study and all her live newborns, as a result of that pregnancy, will be eligible for participation in this study. Mothers will also be eligible to participate with any consecutive pregnancies.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Women who are incarcerated or are unable to consent.\n2. Women whose fetus is not viable or are not planning to continue the pregnancy.",true,"1 Day","99 Years",{"count":85,"type":20},1500,"Background:\n\nChildren s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much weight gain during pregnancy also may have long-term effects on the child s health. Children who become overweight or obese during childhood tend to remain so as adults. Researchers want to study many risk factors during and after pregnancy, and how these affect a child s development. They will also follow the mother s health and well-being after pregnancy.\n\nObjectives:\n\nTo learn how a pregnant mother s environment, lifestyle, and health conditions may affect her child s growth and development from birth until adulthood.\n\nEligibility:\n\nAmerican Indian\u002FAlaska Native (AI\u002FAN) or Hispanic adult pregnant women and their offspring.\n\nDesign:\n\nMothers will have 3 visits during pregnancy.\n\nIn the child s first year, mothers will have 2 visits and their child will have 4.\n\nChildren will have 2 visits in their second year and 1 each year until they turn 18.\n\nMothers will have a visit 2 years after birth and 4-5 years later.\n\nBoth the mother and child s medical records will be reviewed. They will have physical exams and give blood and stool samples.\n\nMothers may give cord blood and placenta samples. They will give breastmilk and urine samples. They will fill out questionnaires.\n\nThey will have an ultrasound. They may get an activity monitor.\n\nMother and child will be followed until the child s 18th birthday.\n\n...",[27,88,89],"Obesity","Fatty Liver",[91,88,92,25,93,94,95],"American Indians, Hispanics","Pregnancy","Children","Hispanics","Natural History","2026-06-27",{"date":33,"type":36},{"date":99,"type":36},"2022-04-14",{"date":101,"type":20},"2041-12-31",{"name":103,"class":104},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":81,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":4,"leadSponsor":125,"locationsCount":105},"100054896","genetic-studies-of-insulin-and-diabetes-100054896","NCT00001987","Genetic Studies of Insulin and Diabetes","Natural History of Disorders of Insulin Resistance","* INCLUSION CRITERIA:\n\nThree categories of subjects will be included in this study:\n\n* Patients with evidence for insulin resistance or a disorder associated with severe insulin resistance, including:\n\n  * Patients with various syndromes of lipodystrophy\n  * Patients with known or suspected mutations on the insulin receptor gene\n  * Patients with known or suspected autoantibodies to the insulin receptor\n  * Patients with other severe forms of insulin resistance\n* Family members of patients, above\n* Healthy control subjects without insulin resistance\n\nInclusion criteria for each group of subjects are given below:\n\n* Patients with evidence for severe insulin resistance or a disorder associated with severe insulin resistance must meet all of the following criteria:\n\n  * Suspected severe insulin resistance, or a disorder associated with severe insulin resistance, as evidenced by one or more of the following:\n  * Hyperinsulinemia (i.e. fasting insulin \\>30microU\u002FmL)\n  * High insulin requirement (\\> 2 units per kg per day or \\> 200 units total per day)\n  * Phenotypic features suggesting a defect in glucose\u002Flipid metabolism:\n\n    * Acanthosis nigricans\n    * Lipodystrophy\u002Fabnormal fat distribution\n    * Xanthomata\n    * Fatty liver\n  * Known or suspected mutations of the insulin receptor gene\n  * Known or suspected autoantibodies to the insulin receptor\n  * Age \\>= 6 months\n  * Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n* Family members of patients, above (either affected or unaffected) must meet all of the following criteria:\n\n  * Biological relatives of patients in category (1) in whom a genetic cause of insulin resistance is known or suspected.\n  * Age \\>= 6 months\n  * Ability of subject (and\u002For legal guardian, for minor subjects) to understand and the willingness to sign a written informed assent\u002Fconsent document.\n* Healthy control subjects Cohort 1 must meet all of the following criteria.\n\n  * Ability of subject (and\u002For legal guardian, for minor subjects) to understand and the willingness to sign a written informed assent\u002Fconsent document.\n  * In good general health with no known active medical conditions as evidenced by medical history\n  * Age \\>= 12 years\n* Healthy control subjects Cohort 2. Subjects from Cohort 1 may be included in Cohort 2 if they meet the following ADDITIONAL inclusion criteria.\n\n  * Fasting glucose \\\u003C100 mg\u002FdL\n  * HbA1c \\\u003C5.7%\n  * Fasting triglycerides \\\u003C150 mg\u002FdL\n  * Fasting insulin \\\u003C30 mcU\u002FmL\n  * BMI \\\u003C27 kg\u002Fm\\^2 or \\\u003C90th percentile for age\u002Fsex (whichever is lower)\n\nEXCLUSION CRITERIA:\n\n* Patients with evidence for insulin resistance or a disorder associated with severe insulin resistance\n\n  --none\n* Family members of patients, above\n\n  --Pregnant at the time of enrollment\n* Healthy control subjects Cohort 1\n\n  * Current use of prescription or non-prescription medication. Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives. Other medications may be permitted at the discretion of the investigators.\n  * Recent (past 2 months) use of drugs or supplements that alter glucose or lipid metabolism (e.g. niacin, fish oil, red yeast rice)\n  * History of diabetes or abnormal glucose tolerance\n  * Psychiatric or cognitive disorder that will, in the opinion of the investigators, limit the subject's ability to provide informed consent\u002Fassent, or to comply with study procedures\n  * Pregnant or lactating\n* Healthy control subjects Cohort 2. Subjects from Cohort 1 may NOT be included in Cohort 2 if they have any of the following ADDITIONAL exclusion criteria.\n\n  * Abnormal screening labs, including the following:\n\n    * ALT or AST more than 1.5 times the upper limit of normal\n    * Glycosuria\n    * Clinically significant anemia\n    * Low eGFR (\\\u003C60 mL\u002Fmin\u002F1.73m\\^2)\n    * Any other abnormality that, in the opinion of the investigator, will increase risk to the subject from participation, or interfere with interpretation of study data","6 Months","120 Years",{"count":116,"type":20},1200,"The study will allow researchers to obtain blood, plasma, DNA, and RNA for genetic studies of insulin. There will be a focus on the causes of insulin resistance and diabetes mellitus. Insulin is a hormone found in the body that controls the level of sugar in the blood. Insulin resistance refers to conditions like diabetes when insulin does not work properly. In this study researchers would like to compare patients with diabetes and other forms of insulin resistance to normal individuals. The study will investigate how insulin attaches to cells.\n\nResearchers will take 4 to 6 ounces (100-150 ml) of blood from adult patients and may request up to 12 ounces (one unit) of blood if necessary. Skin samples may be taken for a biopsy if further genetic testing is necessary. In addition some patients may be asked not to eat for up to 72 hours prior to testing....",[27,119],"Severe Insulin Resistance",[27,119,121,95],"Type B Insulin Resistance",{"date":33,"type":36},{"date":124,"type":36},"1976-02-01",{"name":103,"class":104},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":81,"sex":16,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":56,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":105},"100639438","uppsala-self-screening-of-cardiovascular-health-100639438","NCT07614659","Uppsala Self-Screening of Cardiovascular Health","Uppsala Self-Screening of Cardiovascular Health: A Randomized Controlled Trial of Home-Based Multimodal Cardiovascular Screening Versus Usual Care in Middle-Aged and Older Adults","U-SCREEN","Inclusion Criteria:\n\n* Resident in Region Uppsala, Sweden\n* Turning 50, 55, 60, 65, 70 or 75 years during recruitment period\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Protected identity","50 Years","75 Years",{"count":137,"type":20},45000,[58],"U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.",[63,61,141,27,142,143],"Dyslipidemias","Atrial Fibrillation","Chronic Kidney Disease",[145,146,147,148,149,150,151],"Population screening","Cardiovascular prevention","Home blood pressure monitoring","Dried blood spot","Digital health","Pragmatic trial","Register-based randomized controlled trial","2026-06-26",{"date":33,"type":36},{"date":155,"type":36},"2025-02-01",{"date":157,"type":20},"2037-12",{"name":159,"class":160},"Johan Sundström","OTHER",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":56,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":105},"100635106","spark-cgm-implementation-100635106","NCT07548372","SPARK-CGM Implementation","Supporting Primary Care Adoption, Resources, and Knowledge for Continuous Glucose Monitoring","Inclusion Criteria:\n\nClinic level:\n\n* All adult Montefiore primary care sites\n* Clinician and clinic staff will be eligible if they provide direct patient care or are involved in CGM prescribing, authorization, onboarding, or education at participating primary care clinics. Eligible clinicians include physicians, nurse practitioners, physician assistants, and clinicians in training. Eligible clinic staff may include nurses, medical assistants, and other relevant administrative staff\n\nPatient level:\n\n* Age 18 years or older\n* Receive primary care at participating sites\n* Diagnosis of any diabetes mellitus\n* Treated with insulin therapy\n\nExclusion Criteria:\n\nClinic level:\n\n\\- Sites participating in pilot phase of CGM initiative\n\nPatient level:\n\n\\- Existing CGM prescription within 24 months before the study start",{"count":169,"type":20},20000,[58],"Continuous glucose monitoring (CGM) is a technology that helps individuals with diabetes track their sugar levels in real-time, leading to more in-range blood sugars, fewer episodes of dangerously low blood sugar, and improved quality of life. Despite these benefits, CGM is not widely used in primary care settings, where most people receive their diabetes care. The investigators aim to make CGM more accessible and equitably prescribed in primary care practices. The study team will support primary care to increase CGM use with a program called SPARK-CGM (Supporting Primary Care Adoption, Resources, and Knowledge for CGM) across a large network of primary care clinics at Montefiore Medical Center. This program will provide primary care providers (PCPs) with education, tools, and support to incorporate CGM into their routine care for people with diabetes. Investigators plan to test SPARK-CGM to evaluate whether it increases CGM prescriptions who are eligible to receive this technology.",[27],[174,175,176,177],"Implementation","HbA1c","Multi-component Implementation","Continuous glucose monitoring","2026-06-22",{"date":180,"type":36},"2026-06-23",{"date":182,"type":36},"2026-05-01",{"date":184,"type":20},"2028-05",{"name":186,"class":160},"Montefiore Medical Center",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":56,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":217},"100585805","spyral-gemini-pilot-study-100585805","NCT06907147","SPYRAL GEMINI Pilot Study","Global Pilot Study of rEnal and Hepatic coMbINed denervatIon in Subjects With Uncontrolled Hypertension With and Without High Cardiovascular Risk","SPYRAL GEMINI","Inclusion Criteria:\n\nAll Subjects (both cohorts):\n\n1. ≥18 and ≤80 years of age.\n2. Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \\\u003C180 mmHg and an office DBP ≥ 90 mmHg.\n3. 24-hour average SBP ≥140 mmHg and \\\u003C170 mmHg measured by ABPM at Baseline.\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery OR common hepatic artery anatomy.\n2. Prior renal or hepatic denervation.\n3. History of NYHA Class III or IV heart failure within 6 months of screening visit.\n4. Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability.\n5. Documented Type 1 diabetes or use of insulin within 6 months.\n6. Secondary cause of hypertension.\n7. Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement.\n8. Estimated glomerular filtration rate (eGFR) of \\\u003C40\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Primary pulmonary arterial hypertension.\n11. History or evidence of active \u002F suspected chronic liver or biliary disease.\n12. Current or chronic pancreatitis.","80 Years",{"count":197,"type":20},175,[58],"The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.",[61,62,63,64,27],[202,203,204,205,206,61,63,62,207,208,209],"Renal Insufficiency","Chronic Disease","Disease Attributes","Pathologic Processes","Kidney Diseases","Denervation","Renal Denervation","Hepatic Denervation",{"date":211,"type":36},"2026-06-24",{"date":213,"type":36},"2025-05-01",{"date":215,"type":20},"2029-12-22",{"name":72,"class":43},18,{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":225,"targetDuration":113,"studyType":22,"phases":4,"briefSummary":227,"conditions":228,"keywords":232,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":105},"100644229","effectiveness-of-an-inpatient-rehabilitation-and-prosthetic-training-model-in-patients-with-vascular-and-metabolic-transfemoral-amputation-100644229","NCT07665775","Effectiveness of an Inpatient Rehabilitation and Prosthetic Training Model in Patients With Vascular and Metabolic Transfemoral Amputation","Effectiveness of an Inpatient Multidisciplinary Rehabilitation and Prosthetic Training Model in Patients With Vascular and Metabolic Transfemoral Amputation Treated at a National Rehabilitation Center: An Ambispective Cohort Study","Inclusion Criteria:\n\n* Unilateral transfemoral amputation secondary to vascular disease or diabetes-related complications.\n* Participation in the INRLGII inpatient prosthetic rehabilitation program.\n* Availability of complete clinical records or willingness to participate in follow-up assessments .\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Current prosthesis user before admission to the INRLGII rehabilitation program.\n* Bilateral major lower-limb amputation.\n* Inability to complete follow-up assessments.\n\nWithdrawal Criteria\n\n* Incomplete or inconsistent clinical information.\n* Loss to follow-up during the 6-month observation period.\n* Participant withdrawal of consent.",{"count":226,"type":20},54,"Patients with vascular and metabolic transfemoral amputations experience substantial functional limitations and high rates of prosthetic abandonment. Although multidisciplinary inpatient rehabilitation programs have been associated with improved outcomes, evidence regarding their effectiveness in low- and middle-income countries remains limited.\n\nThis study aims to evaluate the effectiveness of an inpatient rehabilitation and prosthetic training model implemented at the National Institute of Rehabilitation \"Luis Guillermo Ibarra Ibarra\" (INRLGII), Mexico. An ambispective cohort design will be used, including a retrospective review of patients treated between 2013 and 2025 and a prospective cohort enrolled between 2026 and 2029.\n\nThe primary objective is to determine the proportion of patients who achieve functional prosthesis use after hospital discharge. Secondary objectives include identifying clinical, metabolic, functional, and psychosocial factors associated with successful prosthetic use, adherence, and abandonment.",[27,229,230,231],"Transfemoral Amputation","Peripheral Arterial Disease","Vascular Thrombosis",[229,233,27,234,235,236,237,238,239,240,241,242],"Vascular Amputation","Prosthetic Rehabilitation","Lower Limb Amputation","Prosthesis Use","Prosthetic Adherence","Prosthetic Abandonment","Functional Outcomes","Inpatient Rehabilitation","Multidisciplinary Care","Houghton Scale","NOT_YET_RECRUITING","2026-06-18",{"date":211,"type":36},{"date":247,"type":20},"2026-06-19",{"date":249,"type":20},"2030-09",{"name":251,"class":252},"Instituto Nacional de Rehabilitacion","OTHER_GOV",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":16,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":56,"phases":264,"briefSummary":265,"conditions":266,"keywords":271,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100641936","nudging-preventive-screening-via-message-framing-and-bundling-100641936","NCT07644910","Nudging Preventive Screening Via Message Framing and Bundling","The Effect of Message Framing and Screening Bundling on Preventive Screening Engagement: A Randomized Field Experiment","Inclusion Criteria:\n\n* Has at least one pending cancer screening (breast, colorectal, cervical, or prostate) within the contact window, as determined by the medical institution\n* Aged 21 to 74 years\n* Has a valid phone number on file\n* Eligibility is determined operationally before randomization (ex-ante)\n\nExclusion Criteria:\n\n* Participants whose WhatsApp message was not successfully delivered, as reported by the third-party software used by the medical institution.","21 Years","74 Years",{"count":263,"type":20},235000,[58],"This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk\u002FImportance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening.\n\nIn both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes, is not part of the pre-specified analyses, and is thus not described in the \"Arms and Intervention\" section (or counted for \"number of arms\").",[267,268,269,270,27,141],"Breast Neoplasms","Uterine Cervical Neoplasms","Colorectal Neoplasms","Prostatic Neoplasms",[272,273,274,275,276,277,278,279],"Behavioral science","randomized controlled trial","WhatsApp patient outreach","message framing","information avoidance","cancer screening","chronic disease testing","preventive care","2026-06-15",{"date":282,"type":36},"2026-06-17",{"date":284,"type":20},"2026-06-08",{"date":286,"type":20},"2026-12-08",{"name":288,"class":160},"University of Chile",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":16,"minAge":297,"maxAge":298,"enrollmentInfo":299,"targetDuration":17,"studyType":22,"phases":4,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":4},"100642660","glucose-homeostasis-and-shared-genetic-factors-in-colorectal-cancer-100642660","NCT07648589","Glucose Homeostasis and Shared Genetic Factors in Colorectal Cancer","Genetic and Molecular Insights Into Glucose Homeostasis and Colorectal Cancer: Exploring Pleiotropic Genes and Mechanistic Roles in Colorectal Cancer Patients","BRIDGE-CRCDM","Inclusion Criteria:\n\n* Age 20 to 85 years\n* Histologically confirmed colorectal cancer\n* Newly diagnosed colorectal cancer at the time of enrollment\n* No prior diagnosis of diabetes mellitus\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Age younger than 20 years or older than 85 years\n* Pre-existing diagnosis of diabetes mellitus\n* Severe obesity (body mass index ≥35 kg\u002Fm²)\n* Pregnancy\n* Inability or unwillingness to provide informed consent","20 Years","85 Years",{"count":300,"type":20},200,"Colorectal cancer (CRC) and diabetes mellitus are two common diseases that frequently occur together and may share underlying genetic, metabolic, and immune-related mechanisms. Previous studies have shown that diabetes is associated with an increased risk of colorectal cancer and poorer clinical outcomes, while colorectal cancer itself may also influence glucose metabolism.\n\nThis prospective observational study aims to investigate the relationships among glucose homeostasis, shared genetic factors, inflammatory responses, immune cell profiles, and colorectal cancer outcomes. Participants with colorectal cancer and non-colorectal cancer controls will undergo serial assessments of glucose-related biomarkers, inflammatory markers, immune cell populations, and genetic analyses over time.\n\nThe study will focus on identifying shared genetic variants that may contribute to both colorectal cancer and diabetes-related traits, as well as exploring biological pathways involving inflammation, immune regulation, and metabolism. Blood samples and available colorectal tissue specimens will be analyzed to evaluate gene expression, immune cell distribution, and molecular changes associated with disease progression.\n\nThe results of this study may improve understanding of the biological links between colorectal cancer and diabetes, facilitate the development of personalized risk assessment strategies, and identify potential biomarkers and therapeutic targets for patients with colorectal cancer.",[303,27,304],"Colorectal Cancer","Glucose Homeostasis",[303,27,304,306,307,308,309],"Hyperglycemia","SMAD7","Pleiotropic Genes","Cancer Genomics","2026-06-11",{"date":280,"type":36},{"date":313,"type":20},"2026-06-01",{"date":315,"type":20},"2029-05-30",{"name":317,"class":160},"Chang Gung Memorial Hospital",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":56,"phases":328,"briefSummary":329,"conditions":330,"keywords":340,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":360},"100593800","primary-care-pragmatic-real-world-experience-for-automated-insulin-delivery-100593800","NCT07011147","Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery","PREPARE 4 AID","Inclusion Criteria:\n\n1. Age at time of consent \\>18 and \\\u003C89 years\n2. Either 2.a. or 2.b.:\n\n   1. Clinical diagnosis of type 1 diabetes for at least one year and using insulin for at least 1 year\n   2. Clinical diagnosis of type 2 diabetes, on current injected or infused insulin regimen for at least 3 months prior to screening (e.g., basal-bolus, basal only, or pre-mix)\n3. Stable doses of glucose lowering medications over the preceding 4 weeks as determined by Investigator, including GLP-1 receptor agonists (GLP-1 RA) and GLP-1\u002FGIP RA agents\n4. Stable doses of weight loss medications (including GLP-1 RA and GLP-1\u002FGIP RA agents) over the preceding 4 weeks as determined by the investigator.\n5. For those using the iLet Bionic Pancreas (during the RCT arm or observational extension phase), willingness to stay on current doses of medications throughout the study that may affect glycemia directly and\u002For indirectly, except for a dose reduction or discontinuation.\n6. Have a primary care clinician willing to refer them to the study, confirm their diabetes diagnosis (for example: type 1 diabetes or type 2 diabetes), and recommend and manage the iLet for the duration of the study\n7. Willing to comply with all study procedures for the duration of the study\n8. Willing to wear a Dexcom CGM device and iLet system for duration of time randomized to iLet use or OEP\n9. Willing to use the following insulin: lispro (including non-branded lispro and Humalog) or aspart (including non-branded aspart, Fiasp, and Novolog)\n10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol\n11. Willing and able to sign and date the Informed Consent Form (ICF)\n12. If capable of becoming pregnant, willing and able to have pregnancy testing and use an acceptable method of contraception during the study period\n\n    a. Capable of becoming pregnant means that menstruation has started and the participant is not surgically sterile or post-menopausal (12 months without menses) b. Acceptable methods of contraception include: i. Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).\n\n    ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable).\n\n    iii. Placement of an intrauterine device or intrauterine hormone-releasing system.\n\n    iv. Barrier methods of contraception (condom or occlusive cap with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository).\n\n    v. Has a vasectomized or sterile partner (where partner is sole partner of participant) and where vasectomy has been confirmed by medical assessment.\n\n    vi. Exercises true sexual abstinence. Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study.\n13. Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration\n14. Have hardware and internet access capable of 2-way video and audio communication\n\nExclusion Criteria:\n\n1. Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision or dexterity that prevents safe operation of the bionic pancreas, impaired memory)\n2. Unable to speak and read English, as iLet BP support materials and device menus are currently available in English only\n3. Diagnosis of maturity-onset diabetes of the young (MODY)\n4. Plan to change usual diabetes regimen between screening and study randomization\n\n   1. This would include changing from MDI to pump or from pump to MDI, starting a new class of type 2 diabetes medication, or starting or increasing GLP-1 RA or GLP-1\u002FGIP RA medication\n   2. This would NOT include changes to any insulin doses, including pump settings, short- and\u002For long-acting insulin doses and type of insulin; changing type 2 diabetes medication dosing (except GLP-1 RA or GLP-1\u002FGIP RA); or changing type of type 2 diabetes medication within the same class\n5. Weigh more than 255 kg (561 pounds) as this is the maximum weight that can be entered into the iLet user interface\n6. History of bariatric surgery within 12 months prior to enrollment or plans for bariatric surgery within the period of study participation\n7. Current use of a closed-loop or hybrid closed-loop insulin delivery system that is not FDA-cleared (e.g. \"DIY Loop\", \"AAPS\", \"iAPS\" or \"Open APS\")\n8. Diagnosed blood disorder or dyscrasia associated with hemolysis, including for example: sickle cell disease and thalassemia, which in the Investigator's opinion could interfere with HbA1c accuracy\n9. Planned use of hydroxyurea at any dose and\u002For of acetaminophen at doses exceeding 1 gram (1000 mg) every 6 hours.\n10. Plans to receive a blood transfusion over the course of the study or has received a transfusion within 3 months prior to enrollment\n11. Current participation in another diabetes-related clinical trial\n12. History of diabetes due to cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma, or history of complete pancreatectomy\n13. Have a history of intermittent oral or injectable glucocorticoid treatment within 8 weeks prior to screening or plans to take intermittent oral or injectable glucocorticoid during the study (chronic, stable treatment is acceptable, unplanned use is acceptable)\n14. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) in the 6 months prior to screening, unrelated to an intercurrent illness or to a kinked, dislodged, or occluded cannula\n15. Established history of allergy or severe reaction to adhesive or tape that must be used in the study\n16. Treated currently or within the past 30 days prior to enrollment, or plan to begin treatment, with sulfonylurea, pramlintide, or SGLT-2 inhibitor medication\n17. Any planned surgery during the study that would be considered major in the opinion of the investigator\n18. Pregnant or lactating, or planning to become pregnant in the next 6 months\n19. Renal failure on dialysis or chronic renal disease with a GFR or eGFR \\\u003C30mL\u002Fmin (values within the last two years will be accepted; if none available or \\>2 years prior, participant will be instructed to obtain GFR or eGFR through their usual care provider and to make copy of result available to study team)\n20. Any condition or circumstance that, in the opinion of the site principal investigator, could interfere with the safe or effective completion of the study or which could compromise the results of the study c. Conditions to be considered by the investigator may include, but are not limited to, the following: i. Active clinical diagnosis of substance use disorder ii. Chronic use of opiates and\u002For benzodiazepines which, in the opinion of the investigator, might make it difficult for the participant to follow study procedures iii. Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. exercise of intensity up to 6 METS) despite medical management, or within the last 12 months before screening, a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting iv. Known history of prolonged QTc interval, malignant arrhythmia, or severe congenital heart disease v. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV vi. History of TIA or stroke in the last 12 months vii. Untreated or inadequately treated mental illness viii. History of untreated or inadequately treated eating disorder within the last 2 years, such as anorexia, bulimia, or diabulimia, or omission of insulin to manipulate weight ix. History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment\n21. Plans to travel outside of the US and its territories for more than four weeks consecutively\n22. Plans not to have internet\u002Fvideo\u002Fphone access for more than one week consecutively\n23. Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial\n24. Previous use of the iLet for more than four weeks (including use of the commercially available iLet or prior participation in a study involving wearing the iLet for more than four weeks)","89 Years",{"count":327,"type":20},240,[58],"The goal of this randomized controlled trial is to compare the efficacy and safety of the iLet Bionic Pancreas (BP) System in adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes) compared to standard of care when ordered by primary care providers. The main question it aims to answer is:\n\nCan the iLet BP by deployed in primary care settings to adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes)?\n\nResearchers will compare 13-weeks of iLet BP use to routine care to see if iLet BP use has a greater reduction in HbA1c compared to13-weeks of routine care.\n\nParticipants will:\n\nUse the iLet BP for 13-weeks or continue their routine care Be trained to use the study devices or continue their routine care Complete a virtual screening visit, mid-period follow up calls and a final visit Complete baseline CGM collection Complete surveys and fingerstick a1c blood tests Routine care participants will have the option to complete an observational extension phase where they will wear the iLet BP for 13-weeks",[331,332,333,27,334,335,336,25,337,338,339],"Type 1 Diabetes (T1D)","Type 2 Diabetes","Diabetes, Autoimmune","Diabetes Mellitus Type 2","Diabetes Mellitus, Type I","Diabetes, Type II","Diabetes Mellitus, Insulin-Dependent","Diabetes Mellitus Type II","Diabetes Type 2 on Insulin",[341,342,343,344,345,346,347,348,349,350,351],"automated insulin delivery","type 1 diabetes","type 2 diabetes","bionic pancreas","closed loop","pancreas, artificial","t1d","t2d","diabetes","insulin","primary care","2026-06-10",{"date":310,"type":36},{"date":355,"type":36},"2026-01-16",{"date":357,"type":20},"2029-04-01",{"name":359,"class":160},"University of Colorado, Denver",2,{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":385},"100146616","swiss-diabetes-registry---swissdiab-study-100146616","NCT01179815","Swiss Diabetes Registry - SwissDiab Study","Swiss Diabetes Registry - SwissDiab Study, a Prospective Cohort Study of Patients With Diabetes in Switzerland","SwissDiab","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of diabetes mellitus according to ADA criteria\n* Informed consent\n\nExclusion Criteria:\n\n* Patients with gestational diabetes mellitus, patients unable to give informed consent, legally incompetent or incapable to comply with the study terms and conditions as well as patients with significantly reduced life expectancy (\\\u003C1 year) will be excluded",{"count":85,"type":20},"Currently, the estimated number of people with diabetes mellitus is approximately 387 million people worldwide. Due to population growth, urbanization, ageing and the rising prevalence of obesity the numbers of individuals with diabetes is increasing likewise. It has been shown that improving glycemic control is associated with a reduction in late complications of diabetes, such as cardiovascular and microvascular diseases. Therefore, treatment guidelines were established internationally by large and renowned associations and adopted by many countries.\n\nFor Switzerland only sparse data exist on the actual implementation of such recommendations and on patient's well-being. The Swiss Diabetes Registry - SwissDiab Study is a prospective cohort study aiming at including and collecting data of virtually all patients regularly seen and treated at the study centers (≈ 500 patients each), irrespective of type, duration of diabetes or treatment . This allows the evaluation of diabetes treatment strategies at these centers. Furthermore, risk indicators for micro- and macrovascular complications, mortality as well as costs and quality of life will be assessed. Data will be recorded through an internet-based, electronic database specifically designed for this study. At a later perspective it is planned to extend data collection to general practitioner\u002Ffamily doctor networks in order to include a larger and more representative sample of patients with diabetes in Switzerland.",[27],[373,374,375,376,377],"Patients with type 1 or type 2 diabetes mellitus","Monogenetic diabetes","Pancreatogenic diabetes,","Drug-induced diabetes, other forms","Cohort Studies",{"date":310,"type":36},{"date":380,"type":4},"2010-01",{"date":382,"type":20},"2099-01",{"name":384,"class":160},"Insel Gruppe AG, University Hospital Bern",4,{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":135,"enrollmentInfo":393,"targetDuration":4,"studyType":56,"phases":395,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":105},"100643823","phase-3-new-triple-combination-therapy-in-newly-diagnosed-type-2-diabetes-100643823","NCT07635953","New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes","Combination Therapy With Tirzepatide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male or female, 18 years≤age≤75 years at the time of signing informed consent.\n2. Newly diagnosed with type 2 diabetes, or diagnosed within 1 years according to the WHO diagnostic criteria.\n3. Individuals who had not received previous antidiabetic therapy, or had not received antidiabetic therapy within 3 months prior to screening, or had not received antidiabetic therapy for more than 3 consecutive months or a combined total of more than 3 months in the past 2 years.\n4. 6.5%≤HbA1c≤9.0% at screening confirmed by central laboratory analysis.\n5. BMI≥24 kg\u002Fm2.\n\nExclusion Criteria:\n\n1. Individuals with type 1 diabetes or special types of diabetes.\n2. Allergy or intolerance to investigational drugs.\n3. Estimated Glomerular Filtration Rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m².\n4. Individuals with heart failure in New York Heart Association \\[NYHA\\] class III or IV in the 6 months prior to randomization.\n5. History of bladder cancer or hematuria.\n6. History of Multiple Endocrine Neoplasia Type 2 (MEN 2) or relevant family history.\n7. History or family history of Medullary Thyroid Carcinoma (MTC), or susceptibility to MTC due to hereditary conditions.\n8. History of fasting blood glucose≥13.9 mmol\u002FL or the necessity for insulin use due to severe infection, diabetic foot, etc.\n9. History of acute diabetic complications: including diabetic ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis.\n10. Severe diabetic microvascular complications: proliferative retinopathy, or urinary AER\\>300mg\u002Fg, or urinary protein positive, quantitative \\>0.5g\u002F24h.\n11. Uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy.\n12. Severe diabetic macrovascular complications: myocardial infarction, stroke or hospitalization for unstable angina and\u002For transient ischemic attack and\u002For peripheral arterial disease required for vascular intervention or amputation within the 12 months prior to screening.\n13. Blood pressure persistently higher than 180\u002F110 mmHg and not controllable to ≤160\u002F100 mmHg within 1 week.\n14. Alanine Aminotransferase (ALT) ≥2.5 times the upper normal limit, total bilirubin ≥1.5 times the upper normal limit.\n15. Hemoglobin \\\u003C100g\u002FL or requiring regular blood transfusion.\n16. Use of medicines potentially affecting blood glucose for more than 1 week cumulatively in the past 12 weeks, such as corticosteroids, growth hormone analogs, estrogen\u002Fprogestogen, high-dose diuretics, antipsychotic drugs, etc.\n17. Participation in another trial involving medicine therapy within the past 3 months.\n18. Expected lifespan less than 2 years as per the investigator's clinical judgment, e.g., but not limited to malignancy.\n19. Pregnant or lactating females, or females of childbearing potential who cannot or are unwilling to use adequate contraception.\n20. Deemed unsuitable for participation in this clinical trial at the discretion of the investigator.",{"count":394,"type":20},296,[396],"PHASE3","The goal of this clinical trial is to learn the efficacy of combination therapy with tirzepatide, empagliflozin and pioglitazone versus standard therapy in newly diagnosed type 2 diabetes. The main objectives to achieve are:\n\n1. To compare efficacy of the triple combination therapy against standard therapy in achieving type 2 diabetes remission in patients newly diagnosed with T2DM.\n2. To compare the effects on β-cell function and glycemic control of the triple combination therapy against standard therapy in patients newly diagnosed with T2DM Researchers will compare drug new triple combination therapy with tirzepatide, empagliflozin, and pioglitazone to standard therapy (metformin based treatment) to see if new triple combination therapy works better in achieving type 2 diabetes remission.\n\nParticipants will:\n\n1. Take new triple combination therapy or a standard therapy every day for 6 months\n2. Visit the clinic once every 0.5-1 month for checkups and tests\n3. Keep a diary of their fingertip blood glucose and adverse events",[27],"2026-06-03",{"date":401,"type":36},"2026-06-09",{"date":403,"type":20},"2026-07-01",{"date":405,"type":20},"2031-07-01",{"name":407,"class":160},"Sun Yat-sen University",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":16,"minAge":414,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":56,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":105},"100639250","evaluation-of-arts-based-storytelling-program-in-adolescents-with-diabetes-100639250","NCT07625254","Evaluation of Arts-Based Storytelling Program in Adolescents With Diabetes","Inclusion Criteria:\n\n* Participants must be patients at the UCSF Pediatric Diabetes Clinic\n* Participants must have a self-reported diagnosis of diabetes\n* Participants must be between 16-25 years old\n* The participant and\u002For caregiver(s) must be English-speaking\n\nExclusion Criteria:\n\n* Participants unable to attend the first session","16 Years","25 Years",{"count":417,"type":20},10,[58],"The goal of this clinical trial is to evaluate whether an arts-based storytelling and narrative medicine workshop series can improve social connection, illness identity, and psychological well-being in adolescents and young adults with chronic illness, specifically diabetes.\n\nThe main questions it aims to answer are:\n\n* Does participation in a narrative-based storytelling workshop improve social connectedness and peer support among adolescents and young adults with diabetes?\n* Does engagement in creative arts and reflective storytelling support identity formation, self-expression, and emotional well-being in this population?\n\nParticipants will be 16-25 years old and recruited through the UCSF Pediatric Diabetes Clinic. Individuals must be able to participate in group workshops and complete surveys and interviews related to the study.\n\nParticipants will:\n\n* Attend eight weekly workshops centered on storytelling, reflection, and creative expression\n* Engage in narrative medicine activities, including writing, storytelling, drawing, and facilitated reflection\n* Participate in group discussions focused on personal experiences with chronic illness\n* Complete pre- and post-intervention surveys assessing psychosocial outcomes such as social connectedness, illness identity, self-concept, and mental well-being\n* Participate in interviews and reflective exercises about their experiences in the program\n\nThis study aims to explore the role of narrative medicine and arts-based interventions in supporting adolescents and young adults with chronic illness and assess their potential benefits as a supplement to standard medical care.",[27],{"date":422,"type":36},"2026-06-05",{"date":424,"type":20},"2026-06",{"date":426,"type":20},"2026-09",{"name":428,"class":160},"University of California, San Francisco",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":436,"enrollmentInfo":437,"targetDuration":4,"studyType":56,"phases":439,"briefSummary":440,"conditions":441,"keywords":447,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":455,"leadSponsor":457,"locationsCount":105},"100643782","adjunctive-hyaluronic-acid-gel-in-non-surgical-periodontal-treatment-of-patients-with-diabetes-mellitus-100643782","NCT07631273","Adjunctive Hyaluronic Acid Gel in Non-Surgical Periodontal Treatment of Patients With Diabetes Mellitus","The Effect of Hyaluronic Acid on Non-Surgical Periodontal Treatment in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Individuals who sign the informed consent form\n* Participants diagnosed with diabetes mellitus (HbA1c %7-7.9)\n* Participants without any systemic disease other than DM\n* Participants diagnosed with Stage III or Stage IV periodontitis\n* Nonsmokers\n* Participants with at least 15 natural teeth present in the mouth (excluding third molars)\n* Participants in either of the jaws, in both quadrants, having two non-adjacent interproximal sites with probing depth and clinical attachment level ≥6 mm with no caries, restorations or furcation involvement\n\nExclusion Criteria:\n\n* Individuals who do not sign the informed consent form\n* Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis\n* Participants have received any periodontal treatment within 6 months prior to the study\n* Participants who have used antibiotics within the last 3 months\n* Smokers\n* Participants who are pregnant or lactating","65 Years",{"count":438,"type":20},23,[58],"The goal of this clinical trial is to evaluate whether the adjunctive use of hyaluronic acid (HA) improves periodontal healing in people with diabetes mellitus and periodontitis. The effects of HA on biomolecules and bacteria levels will be assessed during the follow-up period.\n\nThe main questions the study will answer are:\n\n* Will periodontal sites treated with non-surgical periodontal treatment (NSPT) plus HA gel show better clinical periodontal parameters than sites treated with only NSPT in patients with diabetes and periodontitis?\n* will HA gel have additional effect on reducing inflammation or collagen markers, and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* provide recent HbA1c test results.\n* then, the participants will receive full-mouth NSPT then, randomization will be performed for the selected jaw for test sites. These two interproximal test sites will additionally receive HA application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels and subgingival samples for periodontal pathogens.",[442,27,443,444,445,446],"Periodontitis","Hyaluronic Acid","Oral Microbiota","IL-34","β-CTX",[442,448,449,443,450,445,446,451],"diabetes mellitus","Non-surgical Periodontal Treatment","Split-mouth Study","periodontal pathogens","2026-06-02",{"date":284,"type":36},{"date":424,"type":20},{"date":456,"type":20},"2028-07",{"name":458,"class":160},"Marmara University",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":360},"100637759","study-of-adult-patients-residing-in-argentina-diagnosed-with-type-2-diabetes-treated-with-a-new-formulation-of-semaglutide-both-oral-and-subcutaneous-in-a-real-world-setting-at-3-months-6-months-and-1-year-of-follow-up-quantifying-the-reduction-in-glycated-hemoglobin-100637759","NCT07621419","Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin","New Formulation of Semaglutide in the Treatment of Type 2 Diabetes in Argentina: a Prospective, Multicenter, Real-world Study","SEMA-REAL ARG","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of type 2 diabetes mellitus.\n* Baseline glycated hemoglobin (HbA1c) \\>7% and ≤12%.\n* Initiating treatment with semaglutide (oral or subcutaneous) prescribed by the treating physician according to clinical judgment.\n\nExclusion Criteria:\n\n* Pregnancy or lactation at the time of enrollment.\n* History of severe hypersensitivity or adverse reactions to glucagon-like peptide-1 (GLP-1) receptor agonists.\n* Contraindications to semaglutide as listed in the product label (e.g., severe gastrointestinal disease, certain endocrine tumors).\n* Any other serious medical condition that, in the investigator's opinion, may interfere with study participation or data interpretation.",{"count":468,"type":20},145,"The goal of this prospective, multicenter, observational study is to evaluate the real-world effectiveness and safety of oral and subcutaneous semaglutide in adults with type 2 diabetes mellitus in Argentina. The main objective is to assess changes in glycated hemoglobin (HbA1c) from baseline to 3, 6, and 12 months after treatment initiation. Secondary objectives include evaluating changes in body weight, waist circumference, hand-grip strength, treatment satisfaction, medication adherence, treatment route switching, treatment discontinuation, and adverse events.\n\nParticipants will receive semaglutide as prescribed by their treating physician as part of routine clinical care. Follow-up assessments will be performed at 3, 6, and 12 months to collect clinical, laboratory, safety, treatment satisfaction, and adherence data. Treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and adherence will be assessed using the Simplified Medication Adherence Questionnaire (SMAQ).",[27],[472,473,474,475,476],"semaglutide","real world study","obesity","type II diabetes","Argentinian Society of Medicine",{"date":452,"type":36},{"date":479,"type":36},"2025-08-04",{"date":481,"type":20},"2028-12-31",{"name":483,"class":160},"Hospital Italiano de Buenos Aires",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":56,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":505},"100633937","phase-3-amaze-2-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-type-2-diabetes-lose-weight-100633937","NCT07533175","AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)","AMAZE 2","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18 years or above at the time of signing informed consent.\n* Diagnosed with type 2 diabetes mellitus more than equal to (≥) 180 days before screening.\n* Treatment with lifestyle intervention, and\u002For 0-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) before screening.\n* Haemoglobin A1c (HbA1c) 7-10% \\[53-86 (millimoles per mole) mmol\u002Fmol\\] (both inclusive) as measured by the central laboratory at screening.\n\nExclusion Criteria:\n\n* Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than (\\\u003C) 30 milliliter per minute per meter square (mL\u002Fmin\u002F1.73 m\\^2) \\[2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\\], at screening.\n* Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) before screening or are expected to require treatment after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8.\n* Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.\n* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.",{"count":493,"type":20},630,[396],"The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[27,497,88],"Overweight",{"date":452,"type":36},{"date":500,"type":36},"2026-04-13",{"date":502,"type":20},"2028-08-07",{"name":504,"class":43},"Novo Nordisk A\u002FS",74,{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":56,"phases":515,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":105},"100506932","continuous-glucose-monitor-for-mayo-clinic-advanced-care-at-home-patients-100506932","NCT05880810","Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients","Continuous Glucose Monitor Use for Mayo Clinic Advanced Care at Home Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Patients who are admitted to Advanced Care at Home (ACH) Program and supposed to remain in ACH for at least 72 hours.\n* Patients with previous diagnosis of DM type 1 or type 2.\n* Patients taking subcutaneous (SQ) insulin either via multidose injections or SQ insulin pump.\n* Capable of giving signed informed consent\n\nExclusion Criteria:\n\n* Actively treated for diabetes ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS).\n* Participants taking acetaminophen more than 4g per day or more than 1gm every 6 hours.\n* Participants with altered mental status.\n* Participants diagnosed with dementia.\n* Patients with suicidal ideations or experiencing suicidal behavior.\n* Patients with liver cirrhosis.\n* Patients with End Stage Renal Disease on dialysis bot hemodialysis or peritoneal dialysis.\n* Participants with allergy to medical grade adhesive or medical tape.\n* Participants taking hydroxyurea.\n* Participants who are pregnant, wanting to become pregnant, or nursing during study period.\n* Patients with a planned MRI within the following 10 days after admission to ACH.\n* Participants currently using continuous glucose monitor (CGM) to dose insulin or check glucose level.\n* Participants with diabetes mellitus (DM) treated with diet alone.\n* Participants with DM treated with oral hypoglycemic medications.\n* Participants with DM treated with one SQ insulin injection daily.\n* Participants enrolled in other studies addressing CGM use.\n* Participants physically or emotionally incapable of handling a cell phone with a smart display.\n* Participants with hearing impaired to a degree that they are not able to hear a smart phone alert or alarm.\n* Patients lacking WIFI or Cellular coverage needed to connect the monitoring cell phone to Internet network.",{"count":514,"type":20},100,[58],"The purpose of this study is to measure differences in diabetes control with the use of continuous glucose monitor (CGM) and diabetes education compared with standard of care for glucose monitoring (glucometer checks) and diabetes education in participants with diabetes mellitus receiving therapy with insulin and being admitted to Mayo Clinic Advanced Care at Home Program (ACH).",[27],[519],"Advanced Care at Home Program (home hospital)",{"date":399,"type":36},{"date":522,"type":36},"2024-05-01",{"date":524,"type":20},"2027-05",{"name":526,"class":160},"Mayo Clinic",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":16,"minAge":533,"maxAge":134,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":105},"100638903","genetic-risk-score-of-type-1-diabetes-mellitus-for-progression-to-insulin-in-diabetic-patients-lack-of-predictive-value-a-multicenter-nested-case-control-study-100638903","NCT07621445","Genetic Risk Score of Type 1 Diabetes Mellitus for Progression to Insulin in Diabetic Patients Lack of Predictive Value: a Multicenter Nested Case-control Study","Inclusion Criteria:\n\n* Gender is not restricted.\n* Age ranges from 14 to 50 years old.\n* Diagnosis of diabetes within \\\u003C 1 year:\n\n  1. If there are diabetes symptoms and meet any of the following criteria:① Plasma glucose at any time ≥ 11.1 mmol\u002FL (200 mg\u002FdL), or② Fasting plasma glucose ≥ 7.0 mmol\u002FL (126 mg\u002FdL), or③ Plasma glucose 2 hours after OGTT\u002Fpost - meal ≥ 11.1 mmol\u002FL (200 mg\u002FdL), or④ HbA1c ≥ 6.5%.\n  2. If there are no diabetes symptoms, another test on a different day is required for diagnosis.\n* Newly - diagnosed diabetes patients whose type diagnosis is considered unclear clinically.\n\nExclusion Criteria:\n\n* Peak C-peptide \\\u003C 200 pmol\u002FL;\n* Gestational diabetes, monogenic diabetes (neonatal diabetes, MODY), exocrine pancreatic diseases (cystic fibrosis), diabetes caused by drugs or chemicals;\n* Those who have been under long-term treatment with hormones or immunosuppressants;\n* Pregnant or lactating women;\n* Those with concurrent malignant tumors or severe heart, liver, and kidney diseases;\n* Those with an expected survival time of less than 3 years;\n* Those with mental disorders or unable to cooperate with the investigation for other reasons;\n* Acute phase of diabetic ketoacidosis;\n* Stress conditions such as severe infection, fever, trauma, and major surgery;\n* Patients lacking major clinical information;\n* Those considered by the researcher as unfit to participate in this study.","14 Years",{"count":535,"type":20},2950,"The goal of this observational study is to evaluate the predictive value of the genetic risk score for type 1 diabetes in the progression to insulin deficiency in diabetic patients. The main question it aims to answer is:\n\n1. To investigate the predictive efficacy of the genetic risk score for T1DM in determining whether diabetic patients will progress to insulin deficiency;\n2. To compare the differences in genetic characteristics between the insulin-deficient cohort and the non-insulin-deficient cohort.\n\nThis study is a nested case-control study, in which a case group and a control group are set up for the collection of observational indicators. Case group: Diabetic patients who \"progressed to insulin deficiency\" and those who \"progressed to severe insulin deficiency\". Control group: Patients who did not progress to insulin deficiency. The study period is 3 years.",[27,538],"Diabetes Mellitus, Type 1",[540],"Genetic risk score","2026-05-31",{"date":452,"type":36},{"date":544,"type":36},"2025-10-27",{"date":70,"type":20},{"name":547,"class":160},"Second Xiangya Hospital of Central South University",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":81,"sex":16,"minAge":53,"maxAge":436,"enrollmentInfo":555,"targetDuration":4,"studyType":56,"phases":556,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":105},"100634520","phase-1-a-study-to-evaluate-the-pharmacokinetics-of-hrs9531-injection-in-participants-with-mild-moderate-and-normal-hepatic-function-100634520","NCT07540754","A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function","A Multi-center, Single-dose, Parallel-group, Open-label Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function","Inclusion Criteria:\n\n1. Participants must fully understand and voluntarily sign a written informed consent form before the trial, demonstrating comprehension of the trial content, procedures, and potential adverse reactions; they must also be willing and able to comply with the protocol requirements to complete the study.\n2. Female participants of childbearing potential must have a negative baseline serum pregnancy test, must not be lactating, and must agree to use contraceptive measures and refrain from egg donation from the time of signing the informed consent form until 2 months after the last dose of the study drug; male participants with partners of childbearing potential must agree to use contraceptive measures and refrain from sperm donation from the time of signing the informed consent form until 2 months after the last dose of the study drug.\n3. Aged 18 to 65 years (inclusive), both male and female.\n4. Male participants weigh no less than 50 kg, and female participants weigh no less than 45 kg. Body mass index (BMI) is within the range of 19.0 to 40.0 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n1. Participation in any clinical trial of a drug or medical device within 3 months prior to dosing, or currently within the follow-up period of a clinical study or within 5 half-lives of the investigational drug (whichever is longer).\n2. Allergic constitution, including a history of severe drug allergy or drug anaphylaxis, excluding untreated asymptomatic seasonal allergies or individuals with positive skin tests only.\n3. Smokers and drinkers who are unable to abstain during the trial period; positive alcohol screening test.\n4. Drug abusers or those with a positive urine drug screening test.\n5. Blood loss or blood donation ≥400 mL within 3 months prior to dosing, or blood loss or blood donation ≥ 200 mL within 1 month prior to dosing, or receipt of a blood transfusion within 3 months prior to dosing.\n6. Undergone any surgery within 6 months prior to dosing, or planned to undergo surgical procedures during the study period.\n7. Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding non-melanoma skin cancer that has been treated with no signs of recurrence, and resected cervical intraepithelial neoplasia).\n8. History of severe hypoglycemia.\n9. Previous significant gastric emptying abnormalities or factors affecting gastric emptying (e.g., history of gastric bypass surgery, pyloric stenosis), or severe gastrointestinal diseases (e.g., active peptic ulcer, inflammatory bowel disease, etc.), or have undergone gastrointestinal surgery (excluding surgeries with no significant impact on gastrointestinal motility, such as removal of gastrointestinal polyps, appendectomy, hemorrhoidectomy, etc.).\n10. Anyone with factors making them unsuitable to participate in this trial evaluated by the investigator.",{"count":44,"type":20},[557],"PHASE1","This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild\u002Fmoderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.",[27,560],"Weight Loss","2026-05-28",{"date":313,"type":36},{"date":564,"type":36},"2026-05-26",{"date":566,"type":20},"2027-02",{"name":568,"class":43},"Fujian Shengdi Pharmaceutical Co., Ltd.",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":195,"enrollmentInfo":577,"targetDuration":4,"studyType":56,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":587,"locationsCount":105},"100637161","efficacy-and-safety-of-modified-orsamr-and-khulood-ors-in-diabetic-pilgrims-during-hajj-100637161","NCT07618702","Efficacy and Safety of Modified ORS(Amr and Khulood ORS) in Diabetic Pilgrims During Hajj","Efficacy and Safety of Modified Oral Rehydration Salts (ORS) in Diabetic Pilgrims With Heat Stress and Dehydration During the Hajj Mass Gathering: A Three-Arm, Active-Controlled, Randomized Clinical Trial","AA-HAMS-ORS","Inclusion Criteria:\n\n* Diabetic pilgrims attending Hajj.\n* Age between 18 and 80 years.\n* Willingness to participate and provide informed consent.\n* Diagnosis of Type 1 or Type 2 Diabetes Mellitus.\n\nExclusion Criteria:\n\n* Patients with severe renal failure.\n* Patients with acute cardiovascular events.\n* Patients unable to take oral fluids.\n* Pregnancy or breastfeeding.\n* Participation in another clinical trial within the last 30 days.",{"count":300,"type":20},[58],"Heat stress and dehydration are significant risks for diabetic pilgrims during the Hajj, often leading to severe complications. Standard Oral Rehydration Salts (ORS) are effective for rehydration but may cause hyperglycemia in diabetic patients due to their glucose content. This study aims to evaluate the efficacy and safety of a modified ORS formula ( Amr and khulood ORS) , specifically designed for diabetic individuals, in maintaining hydration without adversely affecting blood glucose levels. The study will involve a randomized controlled trial comparing the modified ORS (Amr and khulood ORS) with standard ORS among diabetic pilgrims experiencing heat stress. Key outcomes include hydration status, electrolyte balance, and glycemic control.",[27,581],"Heat Stress","2026-05-24",{"date":313,"type":36},{"date":424,"type":20},{"date":586,"type":20},"2027-06",{"name":588,"class":252},"Amr kamel khalil Ahmed",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":16,"minAge":260,"maxAge":195,"enrollmentInfo":596,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":598,"conditions":599,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":610},"100376770","american-indian-chronic-renal-insufficiency-cohort-study-ai-cric-study-100376770","NCT04185844","American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)","AI-CRIC","Inclusion Criteria:\n\n* Glomerular Filtration Rate (GFR): eGFR of =\\>61\\\u003C80 and microalbuminuria \\> 30 or eGRF of =\\\u003C60 (no microalbuminuria required).\n\nExclusion Criteria:\n\n1. Unable or unwilling to provide informed consent\n2. life expectancy \\\u003C3 years;\n3. institutionalized subjects;\n4. End stage renal disease or renal transplant;\n5. renal cancer;\n6. myeloma;\n7. immunosuppression;\n8. Polycystic kidney disease;\n9. participation in any clinical trial,\n10. current pregnancy\n11. current incarceration.\n12. Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.",{"count":597,"type":20},500,"Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - \"CRIC 2018\" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.",[27,64,600,63],"Heart Diseases","2026-05-18",{"date":603,"type":36},"2026-05-20",{"date":605,"type":36},"2020-08-31",{"date":607,"type":20},"2028-06-30",{"name":609,"class":160},"University of New Mexico",3,{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":56,"phases":621,"briefSummary":622,"conditions":623,"keywords":624,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":610},"100512660","comparing-healthcare-visit-recording-and-open-notes-to-improve-chronic-illness-care-experience-in-older-adults-100512660","NCT05955339","Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults","Comparing Healthcare Visit Recording and Open Notes to Improve the Chronic Illness Care Experience for Older Adults (The CHRONICLE Trial)","CHRONICLE","PATIENTS:\n\nInclusion Criteria:\n\n* ≥ 65 years;\n* With multimorbidity (diabetes or hypertension plus one of the following: arthritis (osteoarthritis and rheumatoid arthritis), asthma, atrial fibrillation, Alzheimer's disease and related dementia (not severe), cancer, chronic obstructive pulmonary disease, depression, heart disease, heart failure, hyperlipidemia, osteoporosis, kidney disease and stroke. Patients with diabetes plus hypertension are eligible.\n* Have had two or more clinic visits in the previous 12 months;\n* Plan on receiving ongoing care at the clinic with the enrolled clinician for the subsequent 6 months;\n* Do not have vision or hearing problems that cannot be corrected; and\n* Have not recorded a clinic visit for personal use in the past 6 months\n\nExclusion Criteria:\n\n* With no capacity to consent to the project;\n* With schizophrenia and other psychotic disorders, current substance-use disorders, uncorrected hearing or visual impairment with no adjustments to support accessing the interventions or surveys;\n* Living in skilled nursing homes or hospice, because they engage less in self-management;\n* With cognitive impairment as identified by a score of ≤4 on the six-item screener (SIS)\n* Lacking internet access;\n* Who do not speak English or Spanish;\n* Who (i) do not have access to a personal email, (ii) do not have an email address shared with a family member or patient-identified caregiver, and\u002For (iii) are not interested in creating a personal email as this would prevent them from engaging with the intervention(s); and\n* Who do not wish to create a patient portal account, if they do not already have one as this would prevent them from engaging with the intervention(s).\n\nCAREGIVERS:\n\nInclusion criteria:\n\n* Agree to their identified role as a caregiver;\n* Speak English or Spanish;\n* Have capacity to consent to research participation; and\n* ≥ 18 years.\n\nExclusion criteria:\n\n* No capacity to consent to the project;\n* Living in skilled nursing homes or hospice;\n* Lacking internet access; or\n* Do not speak English or Spanish",{"count":620,"type":20},1022,[58],"CHRONICLE is a randomized trial assessing the comparative effectiveness of providing written visit information via the patient portal (NOTES) versus NOTES plus visit audio recording (AUDIO) to older adult patients with chronic diseases on quality of life and other outcomes. During the trial, the team will also invite caregivers identified by patients to join the project.",[27,61],[625,27,61,626,627,628,629,630,631,632],"Audio Recording","Patient-centered communication","Self-management","Older adults","Chronic conditions","After visit summary","Quality of life","Multimorbidity","2026-05-15",{"date":601,"type":36},{"date":636,"type":36},"2024-01-24",{"date":638,"type":20},"2027-06-14",{"name":640,"class":160},"Dartmouth-Hitchcock Medical Center",{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":16,"minAge":297,"maxAge":648,"enrollmentInfo":649,"targetDuration":4,"studyType":56,"phases":650,"briefSummary":651,"conditions":652,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":105},"100508331","ed-diabetes-screening-and-outpatient-care---aim-3-100508331","NCT05899023","ED Diabetes Screening and Outpatient Care - Aim 3","Identifying Risk Factors for Poor Glycemic Control Among Emergency Department Patients and Improving Linkage to Outpatient Care","Inclusion Criteria:\n\n* Emergency patient receiving lab tests with an initial HbA1c test result of ≥ 6.5%\n* Residential address in New York City or Long Island\n* Primary language is English or Spanish\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* No prior history of diabetes\n* No medical condition that would result in a spurious HbA1c test (e.g., sickle cell, recent blood loss)","70 Years",{"count":300,"type":20},[58],"This goal of this NIH funded R01 study is to identify risk factors for not being able to follow-up for a new diagnosis of diabetes in the emergency department and improve linkage of these newly diagnosed patients to appropriate outpatient care. Its three aims will be accomplished through 1) a retrospective chart review of emergency department (ED) patients screened for diabetes, 2) a series of prospective qualitative interviews among ED patients with newly diagnosed diabetes who fail to follow-up for outpatient care, and 3) a simple randomized controlled trial to test the efficacy of telehealth bridge visits to connect ED patients with newly diagnosed diabetes to outpatient primary care.",[27,653],"Non Insulin Dependent Diabetes Mellitus",{"date":655,"type":36},"2026-05-19",{"date":657,"type":36},"2025-12-01",{"date":659,"type":20},"2028-05-31",{"name":661,"class":160},"NYU Langone Health",{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":56,"phases":671,"briefSummary":672,"conditions":673,"keywords":677,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":685,"leadSponsor":687,"locationsCount":4},"100639513","risk-perception-intervention-for-high-risk-diabetic-foot-100639513","NCT07581262","Risk Perception Intervention for High-Risk Diabetic Foot","Construction and Application of a Foot Ulcer Risk Perception Intervention Program for Diabetic Patients With High-risk Foot Based on Information Framework Effect","Inclusion Criteria:\n\n1. Age ≥ 18 years old with good communication and cognitive abilities.\n2. Meet the World Health Organization (WHO) diagnostic criteria for Type 1 or Type 2 Diabetes Mellitus.\n3. Meet the diagnostic criteria for high-risk diabetic foot according to the International Working Group on the Diabetic Foot (IWGDF) 2023 standards.\n4. Proficient in the use of a smartphone and related applications (e.g., WeChat).\n5. Voluntarily participate in the study and provide signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with impaired consciousness, severe organ dysfunction, or other physical disabilities that lead to being bedbound or unable to perform foot care.\n2. Patients with peripheral neuropathy caused by non-diabetic factors (e.g., toxic, nutritional, or hereditary neuropathies).\n3. Patients with gestational diabetes or those with pre-existing diabetes who are currently pregnant.",{"count":670,"type":20},90,[58],"This study aims to evaluate the effect of health education based on information framing effects on foot ulcer risk perception in patients at high risk of diabetic foot.\n\nStudy Design:\n\nA randomized controlled trial with three groups:\n\nExperimental Group 1 (Gain-Framed): Participants received a benefit framing message that emphasized the benefits of standardized foot care in reducing the likelihood and severity of foot ulcers, with an aim to reshape patients' perception of risk.\n\nExperimental Group 2 (Loss-Framed):Participants received a loss frame message that emphasized that neglecting foot care would increase the likelihood and severity of foot ulcers. The message was designed to awaken patients' awareness of crisis and risk perception.\n\nControl Group (Routine Messaging):Participants received the usual content of care in the endocrinology department without a specific framework.\n\nParticipants:\n\nDiabetic foot patients at high risk from experimental group 1, experimental group 2, and control group 3. Inclusion criteria included adults with a diagnosis of diabetic foot at high risk.\n\nIntervention:\n\nThe Total Study Period consisted of an intervention phase and a follow-up phase. The intervention phase started at the time of enrollment and lasted until the fourth week after discharge. The follow-up period lasted for 3 months. Data on local indicators were collected at baseline\u002Fbefore the intervention (T0), immediately after the intervention (T1), 1 month after the intervention (T2) and 3 months after the intervention (T3).\n\nOutcome Measures:\n\nPrimary Outcomes:\n\nFoot ulcer risk perception: Assessed using The Tripartite Model of Risk Perception Scale.\n\nSecondary Outcomes:\n\nFoot care behavior score: Assessed using The Nottingham Foot Care Assessment Scale; Self-efficacy: Assessed using The Diabetes Self-Efficacy Scale; Intention to delay seeking medical help score:Assessed using the Questionnaire on Intention to Delay Seeking Medical Care for Patients with High-Risk Diabetic Foot; the incidence\u002Frecurrence rate of foot ulcers, and various laboratory indicators.",[27,674,675,676],"Diabetic Foot Ulcer (DFU)","Risk Perception","Peripheral Neuropathy With Type 2 Diabetes",[448,678,679,680],"high risk foot","diabetic foot ulcer","risk perception","2026-05-06",{"date":683,"type":36},"2026-05-12",{"date":182,"type":20},{"date":686,"type":20},"2026-12-31",{"name":688,"class":160},"The Third Affiliated Hospital of Soochow University"]